XML 195 R83.htm IDEA: XBRL DOCUMENT v3.25.1

COMMITMENTS AND CONTINGENCIES (Details Narrativec) - USD ($)			1 Months Ended					3 Months Ended		12 Months Ended
	Dec. 03, 2024	Jul. 02, 2024	Jan. 23, 2024	Nov. 21, 2023	Jun. 26, 2022	Jun. 25, 2022	Jul. 31, 2021	Mar. 31, 2025	Mar. 31, 2024	Dec. 31, 2024	Dec. 31, 2023	Oct. 31, 2024	Jul. 31, 2024
Description for advisory agreement							As consideration for services rendered, and successful Nasdaq listing, the Company paid $100,000. The $100,000 bonus was incurred and settled within 2022. Finally, the Consultant received a total of 10,000 shares of the Company’s common stock, 2,000 of such shares that have been previously issued pursuant to previous agreements and additional 15,258 shares that were issued on February 2, 2023, based on the amendment signed on February 1, 2023
Stock based compensation								$ 0	$ 108,297	$ 2,383	$ 323,957
Payment of additional tax								$ 99,644		$ 99,644
Awarded shares		240,000								240,000
Additional stock consideration		$ 264,000		$ 501,600						$ 264,000
Settelment amount												$ 37,993	$ 37,880
Complementary compensation Shares								440,000		440,000
Purchase price			$ 637,080
Research and Development costs								$ 15,629
General And Administrative Expense [Member] | National Medicines Agency [Member]
Stock based compensation								$ 245,310	$ 231,750	$ 994,160	77,250
Imposed fine										16,214
DOC Pharma S.A. [Member]
Research and Development costs										17,550
Cloud Pharm PC [Member]
Research and Development costs	$ 15,743									$ 0	$ 164,859
Phase 1 [Member]
Project cost					$ 838,450	$ 838,450
Phase 2 [Member]
Project cost					$ 907,084	$ 907,084
Four Third Party Consultants [Member]
Awarded shares				970,000
Awarded share value				$ 999,100

X

- References

No definition available.

+ Details

Name:	cosm_AdditionalStockConsideration
Namespace Prefix:	cosm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_AdvisoryDescription
Namespace Prefix:	cosm_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_ComplementaryCompensationShares
Namespace Prefix:	cosm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_ImposedFine
Namespace Prefix:	cosm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_PaymentTax
Namespace Prefix:	cosm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_ProjectCosts
Namespace Prefix:	cosm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_PurchasePriceAmount
Namespace Prefix:	cosm_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_ResearchAndDevelopmentCosts
Namespace Prefix:	cosm_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	cosm_StockIssuedDuringPeriodSharesAwarded
Namespace Prefix:	cosm_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 14.F)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:	us-gaap_AllocatedShareBasedCompensationExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Fair value amount of life settlement contracts accounted for under the fair value method.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 325
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481493/325-30-45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 325
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481463/325-30-50-8

+ Details

Name:	us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

X

- Definition

Amount of other research and development expense.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 730
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1

+ Details

Name:	us-gaap_OtherResearchAndDevelopmentExpense
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

The fair value of stock issued in noncash financing activities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-4

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-3

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482913/230-10-50-5

+ Details

Name:	us-gaap_StockIssued1
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	srt_LitigationCaseAxis=cosm_NationalMedicinesAgencyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_DocPharmaSaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_CloudPharmPCMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseOneMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_PhaseTwoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=cosm_FourThirdPartyConsultantsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: